Skip to main content
OpenTrials
Completed

NCT Number: NCT05996796

Dry Run of the ScreenUrSelf Trial

The proposed study is the Dry Run preceding the ScreenUrSelf trial.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The ScreenUrSelf trial will be embedded in the Flemish organized cervical cancer screening program. The goal of ScreenUrSelf is to reach women who are eligible but do not participate in cervical cancer screening, by offering two self-sampling methods (first-void urine and vaginal) in an opt-in and -out strategy (total of four interventions) to collect samples for primary high-risk (hr) Human Papillomavirus (HPV) testing, and if positive, reflex 1) cytology on a Pap smear (standard of care) and 2) methylation marker triage (index test). The two control arms include 1) no intervention; and 2) sending (recall) invitation letters to women, inviting them to make an appointment for a Pap smear (i.e., current practice within the organized cervical cancer screening program in Flanders).

The Dry Run which is the subject of this clinical trial will test the study materials and data flows developed for the interventional study arms (C, D, E and F) of the ScreenUrSelf trial. The primary outcome of the Dry Run is to check if the flow for data- and sample collection is ready for start of the ScreenUrSelf trial, and if optimizations are deemed necessary before start of the trial.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eligible for cervical cancer screening within the organized Population-based Screening Program in Flanders:
  • Female
  • Residing in Flanders, Belgium
  • No history of total hysterectomy
  • No (former) diagnosis of cervical or uterine cancer
  • 30 - 64 years old (birth year 1959 - 1992)

Exclusion criteria

  • Being pregnant or 6 weeks postpartum (self-reported after receiving the study letter/package)
  • Participation during menstruation or within the 3 following days is a contraindication
  • Not able to understand the study materials and participation form (informed consent form)

Treatment and study plan

Colli-Pee Small Volumes

Device

Women will self-collect a first-void urine sample at home upon receipt of the study package using the Colli-Pee Small Volumes (10 mL) device (Novosanis, Belgium). The collector tube is prefilled with a preservative (UCM, Novosanis, Belgium). Women will send the collector vial containing first-void urine along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.

Evalyn Brush

Device

Women will self-collect a vaginal sample at home upon receipt of the study package using the Evalyn Brush device (Rovers Medical Devices, The Netherlands). Women will send the used brush along with the informed consent form to the laboratory at University of Antwerp using the prestamped envelope.

Primary outcomes

  1. HPV DNA using the Riatol qPCR HPV genotyping assay

    Time frame: Through study completion, an average of 1 year

    HPV DNA concentration [copies/µl DNA] in self-samples from all study participants.

Secondary outcomes

  1. Human DNA (Beta-globin) using the Riatol qPCR HPV genotyping assay

    Time frame: Through study completion, an average of 1 year

    Human DNA concentration [copies/µl DNA] in self-samples from all study participants

  2. Preferences

    Time frame: Through study completion, an average of 1 year

    Preferences and attitudes of women regarding self-sampling (measured using a questionnaire)

Sponsors and collaborators

Lead sponsor

Universiteit Antwerpen

Other

Collaborators

  • Antwerp University Hospital (UZA)
  • Centre for Cancer Detection (CvKO)
  • Sciensano

Registry information

Official study title

Cervical Cancer Screening Based on First-void Urine Self-sampling to Reach un(Der)-Screened Women: Dry Run of the ScreenUrSelf Trial

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Aug 18, 2023
Registry last updated
Aug 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.